62 results about "HSP60" patented technology

The present invention provides methods for efficient and concomitant recovery of multiple chaperone proteins and/or chaperone protein complexes from a limited sample source. Disclosed are methods involving the use of Free Solution Iso-Electric Focusing (FS-IEF) which can enrich samples containing chaperone proteins and/or chaperone protein complexes from a given sample. The chaperone proteins can be, but are not restricted to calreticulin, gp96, hsp86, hsp84, hsp70, hsp60 and hsp40. The invention also provides methods of recovering chaperone protein complexes for the preparation of vaccines containing chaperone complexes.

The present invention relates to a detection chip for performing gene detection to various vibrio and its detection and applications. The invention provides 16S rRNA sequences corresponding to each vibrio of vibrio anguillarum, vibrio harveyi, vibrio alginolyticus, vibrio parahaemolyticus, brilliant vibrio and Fisher vibrio; heat shock protein hsp60 probe sequence; virulence gene probe sequence; 16S rRNA forward primer sequence; 16S rRNA reverse primer sequence; heat shock protein hsp60 forward primer sequence; heat shock protein hsp60 reverse primer sequence; virulence gene forward primer sequence and virulence gene reverse primer sequence. The present invention has specific, sensitive and high-throughput features, can simultaneously detect six kinds of bacteria virulence genes, and the invention will effectively guide the production as an important disease early-warning detection method used in clinical diagnosis of aquatic animals.

The invention provides a kit for detecting an Alzheimer autoantibody in serum. The kit comprises an antigen protein combination, the antigen protein combination contains at least four proteins, and the proteins are selected from RABPT5, RAGE, CRYAB, SRPK1, MAPT, MBP, PLP1, PTCD2, FRMD8, POMC, DNAJC8, CENTA2, HSP60, ADARB1, ASXL1, EDRK, GDF11, P21, CCL2, IL18, VEGF, LENG1 and MRPL34. The inventionfurther provides application of the limited antigen protein combination to preparation of a reagent for detection, diagnosis or risk prediction of Alzheimer, and methods for detection, diagnosis or risk prediction of Alzheimer.

The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.

The invention provides the immunomodulator with the free adjuvant having the function of preventing and curing the insulin-dependent diabetes mellitus. Aiming at the weak immunogenicity, the antigen epitope polypeptide gene (a length of antigen epitope p277 rooted from human HSP60) is associated repeatedly six times and inserted repeatedly into the backward position of the heat shock protein HSP65 gene rooted from the mycobacterium bovis, the fusing expression between the repeat series connecting antigen polyeptide and the HSP65 is realized. The produced fusing albumen did not need the adjuvant; the antigen polyeptide don't need be coupled with the carrier chemistry to the immunity. The fusing albumen can inspire the organism to produce the high titer aiming at p277 by means of the mucous membrane immunity, so the nosogeny of NOD chmice diabetic are depressed highly. The invention can prevent the 1 type and 1.5 type diabete characterized in depending on the insulin.

The invention provides peptide used for preventing and treating diabetes. According to the weak immunogen of antigen polypeptide, a fragment of antigenic epitope (IPALDSLTPANED) derived from HSP60 is inserted into the downstream of a linear B-epitope sequence HGDTTDEYQD in a membrane closing area of insulinoma associated protein 2 to form the peptide. According to the peptide, the generation times of NOD (nonobese diabetic) mice diabetes can be reduced obviously, so that the novel peptide plays the role of preventing and treating I-type diabetes. Meanwhile, the peptide can be used for transgenic animals and recombinant microorganisms, so that the transgenic animals and the recombinant microorganisms can be used for producing the peptide or preparing oral vaccine for preventing and treating diabetes and related diseases of diabetes.

The present invention fragments and analogs of heat shock proteins in combination with a low antigenicity diet for suppression, prevention and treatment of diabetes. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet. The invention further relates to orally active pharmaceutical compositions comprising Hsp60 fragments and analogs, such as DiaPep277, useful for suppression, prevention or treatment of diabetes and to a regimen for delaying the onset of type 1 diabetes and for inhibition of insulitis.

The invention belongs to the immunology field, in particular to a proteantigen molecule-Japanese blood fluke heat shock protein 60KDa (SjHSP60) which is derived from a blood fluke and is capable of increasing CD4 + CD25 + Foxp3 + regulatory T cells and application thereof. The SjHSP60 has a full-length amino acid sequence as shown in SEQ.ID.NO.1, has a series of identical or highly similar cross-reactive T cell epitopes with HSP60 infected by a host. After being used for mouse in vivo immunization or in vitro stimulus to mouse spleen and lymph gland cells, the SjHSP60 can obviously increase CD4 + CD25 + Foxp3 + Tregs. In practical application, the SjHSP60 can effectively relieve inflammatory symptoms and immunopathological effects caused by arthritis, thereby having wide prospects in the aspects of immunological suppression inducement and treatment of immunological diseases.

The invention discloses the bilobalide application of preparing medicine that treats paralysis agitans. The bilobalide is effective for mouse paralysis agitans, and the mechanism is relevant with the activation of bilateral regulation NF-kb, reduced expression of apoptosis-promoting protein p53 and iNOS, and increased expression of apoptosis-resisting protein Bc1-2 and HSP60.According to this result, it can be proven that bilobalide can treat paralysis agitans at a certain degree.

The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.

The invention relates to an immune modulator for treating arteriosclerosis. Aiming at antigen peptides's weak immunogenicity, a series of epitopes peptides of antigens (SEQ ID NO.1) originating from heat shock protein (HSP60) are inserted into the downstream of Cholera toxin B subunit(CTB), and fusion expression of antigens epitopes peptides and CTB is realized. Produced fusion protein (CTB-p277) and Heat shock protein 65 (HSP65) are coupled chemically, without adjuvant, and directly used immunization. The coupled protein can stimulate body to produce high titer antibody aiming at P277 through mucosal immunity pathway, obviously inhibit occurrence of New Zealand white rabbits's arteriosclerosis, and can have a function for treating arteriosclerosis.

The invention discloses a flavone alkoxy phosphoramidate derivative for targeted Hsp60, a preparation and application. The flavone alkoxy phosphoramidate derivative for the targeted Hsp60 has the advantages of simple and easy preparation method and low cost. A series of novel flavone alkoxy phosphoramidate derivative with anti-tumor activity is designed and synthesized to realize an obvious inhibition and killing effect on breast cancer cells and hepatoma carcinoma cells and realize no obvious inhibition effect on normal hepatocyte. The flavone alkoxy phosphoramidate derivative for the targeted Hsp60, disclosed by the invention, has the advantages that the selective flavone alkoxy phosphoramidate derivative for the targeted Hsp60 is developed, and the flavone alkoxy phosphoramidate derivative for the targeted Hsp60 has very good practical values and application prospects in the field of preparing anti-tumor drugs.

The invention discloses a recombinant expression carrier containing a schistosoma japonicum gene which is a schistosoma japonicum heat shock protein 60 gene. The invention also discloses a preparation method of the schistosoma japonicum heat shock protein 60 and the application of the recombinant expression carrier. The recombinant expression carrier containing the schistosoma japonicum gene can highly express the schistosoma japonicum heat shock protein 60 gene, and the highly expressed recombinant schistosoma japonicum Hsp60 protein can induce mouse to generate the protection function of resisting the infection of schistosoma japonicum at a certain level.

The present invention provides one kind of restructuring protein and its restructuring gene for preventing and treating type-1 diabetes. Connecting heat shock protein HSP60 originated Mycobacterium bovine to a piece of antigen epitope P277 from human HSP60; restructuring protein produced can be used for immunity directly with no adjuvant. The restructuring protein can stimulate body to produce antigen for P277 both by ways of injection and mucous membrane immunity, decreases marked NOD mouse diabetes occur, can contribute to preventing and caring type-1 diabetes. Meantime, the restructuring gene produced in this invention can also be used to transgene animals or plants and restructuring microorganism as the factory for producing restructuring protein or preparing oral vaccine.

The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.

The invention discloses an optimized recombinant antigen polypeptide Abeta1-15-HSP60 nucleotide sequence and a method of efficiently solubly expressing in Escherichia coli. The method comprises the following steps: optimizing the recombinant antigen polypeptide Abeta1-15-HSP60 nucleotide sequence, constructing a pCold/Abeta1-15-HSP60expression vector, inducing a foreign protein expression in Escherichia coli with IPTG at low temperature, wherein the quantity of foreign protein expression can achieve more than 50% of total bacterial protein, and the soluble expression quantity achieves more than 90% of total expression quantity. The method can be used for efficiently preparing the recombinant antigen polypeptide Abeta1-15-HSP60.

Described is a method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell. The method consists in using the study of the protein expression of the bioenergetic function of the mitochondrion, such as the beta-catalytic subunit of the H-ATP synthase, in relation to structural proteins and mitochondrial respiration, such as hsp 60 and cytochrome oxidase subunits I and IV respectively, and said mitochondrial bioenergetic index, (ratio of beta-ATPasa/hsp60; beta-ATPasa/COX I; beta-ATPasa/COX IV) which relates to the cellular protein expression of the glycolytic pathway, such as glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M, in order to generate the bioenergetic index of the cell.